Drug intelligence / Profile preview

BBI-3000

Development stage: Discontinued
Lead developer: Fresh Tracks Therapeutics
Modality: Small Molecules
Administration: Topical

Overview

**BBI-3000** is a small molecule retinoid-X receptor (RXR) agonist developed by Fresh Tracks Therapeutics (formerly Brickell Biotech) for topical treatment of dermatological conditions. It exhibits a differentiated activity profile compared to leading topical retinoids, potentially offering improved efficacy or tolerability. Development has been discontinued for its lead indications.[1][4][10]

Targets

RXRA (Retinoid X receptor alpha)

Beyond the preview

Go deeper on BBI-3000.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BBI-3000.

Explore the full profile